Equities

Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc

Actions
  • Price (USD)0.90
  • Today's Change0.062 / 7.44%
  • Shares traded2.65k
  • 1 Year change-90.21%
  • Beta2.6734
Data delayed at least 15 minutes, as of May 17 2024 20:54 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

  • Revenue in USD (TTM)0.00
  • Net income in USD-20.48m
  • Incorporated1999
  • Employees18.00
  • Location
    Eloxx Pharmaceuticals Inc480 ARSENAL WAY, SUITE 130WATERTOWN 02472United StatesUSA
  • Phone+1 (781) 577-5300
  • Fax+1 (302) 636-5454
  • Websitehttps://www.eloxxpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Windtree Therapeutics Inc0.00-20.29m2.66m15.00--7.94-----8.21-8.210.000.56550.00----0.00-57.68-44.51-63.50-48.38-------94,533.34----0.8179------48.25------
AgriFORCE Growing Systems Ltd16.28k-11.73m2.69m7.00--0.0705--165.21-14.14-14.140.0141.470.0008--0.4082,325.71-59.84-78.95-84.37-109.8616.58---72,071.25-243,182.500.6922-1.390.3253------8.85--48.61--
60 Degrees Pharmaceuticals Inc253.57k-3.99m2.73m3.00------10.77-0.6657-0.66570.04560.83820.05590.96381.8384,523.34-84.00-------87.15---1,504.04--2.39-1.890.0321---50.40--35.51------
cbdMD Inc21.58m-25.65m2.77m52.00--0.707--0.1283-19.96-19.969.271.010.89492.0921.27415,039.60-89.78-38.59-118.26-41.5062.7063.80-100.33-87.980.6107-3.010.4668---31.77120.9163.64---4.95--
Panacea Life Sciences Holdings Inc2.76m-7.67m2.81m40.00------1.02-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.124.79--46.59--12.33------
Novelstem International Corp12.00k-4.19m2.81m15.00------234.41-0.0893-0.08930.0003-0.04160.0053--2.00---171.11---188.15-------32,373.50-----9.822.20--0.00---446.84------
Eloxx Pharmaceuticals Inc0.00-20.48m2.83m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Resonate Blends Inc16.47k-1.42m2.84m6.00------172.21-0.0178-0.01780.0002-0.02470.0237-------203.52-680.29-----593.02-78.88-8,597.33-12,895.26---0.46917.89---66.73-56.57-316.63------
Avenue Therapeutics Inc0.00-7.18m2.87m3.00--0.7762-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Mosaic Immunoengineering Inc0.00-1.01m2.90m3.00---------0.1397-0.13970.00-0.81070.00----0.00-457.45-----------------35.84--------57.65------
Regen BioPharma Inc236.58k-851.69k2.90m1.00------12.26-0.2271-0.22710.0633-1.260.8644--3.98236,580.00-327.54-104.36---------378.93-275.00---1.32----0.441618.79-58.11------
Axim Biotechnologies Inc39.77k-8.06m2.91m6.00------73.29-0.0366-0.03660.0001-0.03110.0095----6,628.33-193.43-154.34---390.73-----20,265.75-36,362.71---0.62----345.05-27.38-29.10------
Veritas Farms Inc730.65k-6.15m2.95m17.00--14.57--4.04-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
Livewire Ergogenics Inc67.98k-1.09m2.98m1.00------43.78-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Biostax Corp0.00-1.65m3.01m-----------0.0198-0.01980.00-0.04560.00-------193.36-75.14---------------8.97--------53.32------
Data as of May 17 2024. Currency figures normalised to Eloxx Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Old Point Trust & Financial Services, NA (Invt Mgmt)as of 31 Mar 202462.000.00%
Clal Pension & Provident Funds Ltd.as of 31 Mar 20240.000.00%
Menora Mivtachim Insurance Ltd.as of 31 Mar 20240.000.00%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.